Ilios develops multi-functional small molecules that target protein misfolding, oxidative stress, and neuroinflammation to combat neurodegenerative diseases like Alzheimer's and ALS-FTD. Their chemistry platform merges bioactive pharmacophores with glutathione and fatty acids to create compounds that effectively penetrate the brain and address the underlying mechanisms of these disorders.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HIFounders
Product
Problem
Neurodegenerative diseases like Alzheimer's and ALS-FTD are characterized by multiple pathological processes, including protein misfolding, oxidative stress, and neuroinflammation. Addressing these interconnected mechanisms requires multi-faceted therapeutic interventions that can effectively reach the brain.
Solution
Ilios is developing multi-functional small molecules designed to simultaneously target protein misfolding, oxidative stress, and neuroinflammation, key drivers of neurodegenerative diseases. Their chemistry platform combines bioactive pharmacophores with glutathione and fatty acids to create compounds with enhanced brain penetration. This approach aims to deliver drugs that can modulate multiple disease processes, overcoming the limitations of single-target therapies. By addressing the underlying mechanisms of neurodegeneration, Ilios seeks to develop effective treatments for diseases like Alzheimer's and ALS-FTD.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and investors interested in novel therapeutic approaches for neurodegenerative diseases.
Features
- Multi-functional small molecules targeting protein misfolding, oxidative stress, and neuroinflammation
- Chemistry platform merging bioactive pharmacophores with glutathione and fatty acids
- Rational design for enhanced brain penetration
- Lead program focused on ALS-FTD, addressing TDP-43 mislocalization, NRF-2 dysregulation, and microglial inflammation
- Pathophysiology-specific functional screens for compound validation